Mereo BioPharma (MREO) Return on Invested Capital (2023 - 2024)
Mereo BioPharma (MREO) posted quarterly Return on Invested Capital of 0.03% for Q1 2024, down 57.01% on a QoQ basis from 0.02% in Q4 2023.
Mereo BioPharma (MREO) Return on Invested Capital (2023 - 2024) Analysis & Trends
Mereo BioPharma (MREO) has reported Return on Invested Capital for 2 consecutive years, with 0.03% the latest figure, recorded in Q1 2024.
- Quarterly Return on Invested Capital changed N/A year-over-year to 0.03% in Q1 2024, while the trailing twelve-month figure through Mar 2024 was 0.03% (changed N/A YoY) and the FY2022 annual result came in at 0.03%, down 2.0% from the prior year.
- Return on Invested Capital fell to 0.03% in Q1 2024 per MREO's latest filing, from 0.02% in the prior quarter.
- Over the last five years, Return on Invested Capital for MREO reached as high as 0.02% in Q4 2023 and fell as low as 0.03% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Mereo BioPharma | 235.73 Mn | 235.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -0.03% |
| Dec 31, 2023 | -0.02% |